Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 14, 2025, SpringWorks Therapeutics, Inc. (the "Company") held its annual meeting of stockholders to consider and vote on the proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 4, 2025. The final voting results are set forth below.

Proposal 1 - Election of Directors

The stockholders elected the person named below to serve as a Class III directors of the Company for a three-year term that expires at the Company's annual meeting of stockholders in 2028 and until their successors have been duly elected and qualified, subject to their earlier death, resignation or removal. The results of such vote were as follows:

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of such vote were as follows:

Proposal 3 - Non-Binding Advisory Vote on Executive Compensation

The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the annual meeting of stockholders. The results of such vote were as follows: